Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as ...

Offering a blood test as a secondary option in individuals who previously declined colonoscopy or FIT increased CRC screening by 7.5%. There was no decrease in uptake of first-line screening options.

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

A blood-based colorectal cancer test was found to be the most cost-effective alternative colorectal cancer test for people who didn’t want a colonoscopy or fecal immunochemical test, according to a ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Blood-based liquid biopsy tests for colorectal cancer (CRC) are in development and may soon hit the market, expanding potential options for patients who refuse traditional colonoscopy. But would they ...

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...

Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...

PALO ALTO, Calif., November 05, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...